Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01562157 | DOI Listing |
PLoS One
January 2025
Brain and Mind Institute, Aga Khan University, Nairobi, Kenya.
Introduction: Self-harm represents a complex and multifaceted public health issue of global significance, exerting profound effects on individuals and communities alike. It involves intentional self-poisoning or self-injury with or without the motivation to die. Although self-harm is highly prevalent, limited research has focused on the patterns and trends of self-harm among hospital populations in low- and middle-income countries, particularly within Africa.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Obstetrics and Gynecology, Nahdi Care Clinics, Jeddah, Saudi Arabia.
Introduction: Although COVID-19 vaccines have been recommended for children and adolescents since 2021, suboptimal vaccination uptake has been documented. No previous systematic review/meta-analysis (SRMA) investigated parents' willingness to administer COVID-19 vaccines for their children in Saudi Arabia. Accordingly, this SRMA aimed to estimate parents' willingness to immunize their children with COVID-19 vaccines in Saudi Arabia and to identify reasons and determinants influencing parents' decisions.
View Article and Find Full Text PDFProstate
January 2025
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, Michigan, USA.
Introduction: PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim to examine the percentage of patients in real-world practice who get PSA screening as defined by each of the aforementioned trials.
View Article and Find Full Text PDFAustralas J Ageing
March 2025
Department of Geriatric Medicine, Austin Health, Heidelberg, Victoria, Australia.
Objectives: Residential aged care respite clients are vulnerable and prone to poor health-care outcomes. Improvements in the quality of care for this cohort are urgently needed. However, before proposing changes in care models, a nuanced understanding of relevant issues affecting respite care consumers and professionals is required.
View Article and Find Full Text PDFAnnu Rev Med
January 2025
Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus and Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; email:
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials-elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant-with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!